STAT June 12, 2024
Jason Mast

Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed to slow the disease’s progression in a Phase 3 trial.

This is now the second large, randomized, placebo-controlled trial of a Duchenne gene therapy to fail to reach its primary endpoint, a composite scale of muscle function designed specifically for the rare disease. A similar study...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
Enhancing Target Screening with CRISPR Libraries: Revolutionizing Drug Discovery and Functional Genomics
Daiichi Sankyo Announces New CEO

Share This Article